Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cancer-associated cachexia is a multifactorial wasting disorder characterized by anorexia, unintentional weight loss (WL, skeletal muscle mass with or without loss of fat mass), progressive functional ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...

A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups. An analysis of ...

DelveInsight’s ‘Cancer Cachexia Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia epidemiology in the 7MM, i.e., the ...

Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, alongside extreme fatigue, anorexia and anemia in ...

Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...